The Effects of Acute vs. Chronic of Screen Illumination on: Sleep Efficacy and Architecture, Physiology, Emotion and Behavior: Possible Effect on Human Health
1 other identifier
interventional
19
0 countries
N/A
Brief Summary
The human eye has a dual role, which is reflected by the various photo-receptors used for vision of images and colors ,Image forming photoreceptors (IFP) and for entrainment of our "Biological clock" located in the hypothalamus through the retinal ganglions known as non-image forming photoreceptors (NIFP). The recently discovered new photo-pigment melanopsin which is sensitive to short wavelength (SWL) illumination exists in the-NIFP. The axons of the NIFP form a special nerve known as the Retino-hypothalamic-tract (RHT) that transfers the SWL signal to the biological clock resulting in suppression of pineal melatonin (MLT) production. This is the basic mechanism by which environmental light/dark cycles entrain the biological clock and transfer the message to organs, tissues and cell. The American Medical Association (AMA) issued a resolution in 2012 stating that light at night constitutes environmental pollution because it violates the daily cycles, including the waking and sleeping cycles, and suppresses the secretion of melatonin from the pineal gland at night. Results of other studies have shown that exposure to artificial light at night (ALAN) and mainly those emerging from SWL sources suppresses MLT-produced in the pineal gland. Computers, tablets, TVs, and smart-phones screens emit SWL illumination, during the day and night hours, whether as active or passive users. The results of previous studies show that, exposure to SWL-ALAN illumination suppresses MLT-secretion and disrupts sleep patterns. In order to understand better the effect of SWL-exposure emerging from screens on human behavior and health, the investigators will study the effects of SWL-exposure on the structure and quality of sleep, cognitive functioning in Continous Performance Test (CPT III), emotional state, and physiological, variables (melatonin secretion levels and body temperature) that were not tested in previous studies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable
Started Aug 2016
Shorter than P25 for not_applicable
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 7, 2016
CompletedFirst Posted
Study publicly available on registry
July 21, 2016
CompletedStudy Start
First participant enrolled
August 1, 2016
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 1, 2016
CompletedStudy Completion
Last participant's last visit for all outcomes
December 1, 2016
CompletedJanuary 9, 2018
January 1, 2018
2 months
July 7, 2016
January 8, 2018
Conditions
Keywords
Outcome Measures
Primary Outcomes (15)
body temperature
body temperature in celsius degree.physiological marker
12 hours
Melatonin secretion
Melatonin -Sulfate Urine ELISA 6-SMT ng/ml. physiological marker
12 hours
sleepiness
ESS questionnaire score- number
1 day
BSI Questionnaire
assess the subject's emotional state- number
1 day
Subjective sleepiness
KSS questionnaire-number
1 day
attention
a neuropsychological computerized attention and concentration test, designed to test attentional functions. number
1 hour
total Sleep time
total sleep time in minutes. physiological marker
1 night
Sleep efficiency
percentage of sleep efficiency- physiological marker
1 night
sleep latency to sleep stage1
time in minute to sleep stage 1. physiological marker
1 night
sleep latency to sleep stage2
time in minute to sleep stage 2. physiological marker
1 night
wake %TIB
percentage of wake from Time in bed. physiological marker
1 night
REM %TIB
percentage of REM from Time in bed. physiological marker
1 night
staege1%TIB
percentage of sleep stage1 from Time in bed. physiological marker
1 night
stage2%TIB
percentage of sleep stage2 from Time in bed.physiological marker
1 night
stage4%TIB
percentage of sleep stage4 from Time in bed.physiological marker
1 night
Study Arms (3)
base line
ACTIVE COMPARATORFirst night is the base line- no exposure to computer screen illumination.
Acute
EXPERIMENTALSecond night is the acute exposure to computer screen illumination.
Chronic
EXPERIMENTALChronic is the effect after five nights of exposure to computer screen light illumination.
Interventions
the subject will sited in a dim light room. No screen light illumination.
The subject will be sited in front of computer screen light illumination for 2 hours.
The subject will be sited in front of computer screen light illumination for 2 hours for 5 consecutive days.
Eligibility Criteria
You may qualify if:
- age 20-45,
- healthy
- No history of visual disturbances
- No history of sleep disorders
You may not qualify if:
- score more then 5 in the Pittsburgh Questionnaire (PSQI).
- Subjects with a-typicality deviation in the HORNE - OSTBERG sleep-wakefulness cycle questionnaire.
- One of the Eye problems: field of vision, color blindness, or impaired functioning of the pupil in reaction to light.
- Subjects who did shiftwork three months before the experiment
- Subjects that taking sleeping medications in general and melatonin in particular
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- NON RANDOMIZED
- Masking
- SINGLE
- Who Masked
- PARTICIPANT
- Purpose
- BASIC SCIENCE
- Intervention Model
- SINGLE GROUP
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Dr.
Study Record Dates
First Submitted
July 7, 2016
First Posted
July 21, 2016
Study Start
August 1, 2016
Primary Completion
October 1, 2016
Study Completion
December 1, 2016
Last Updated
January 9, 2018
Record last verified: 2018-01
Data Sharing
- IPD Sharing
- Will not share